These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 33189635)

  • 1. Cause of Death in Patients With Acute Heart Failure: Insights From RELAX-AHF-2.
    Loungani RS; Teerlink JR; Metra M; Allen LA; Butler J; Carson PE; Chen CW; Cotter G; Davison BA; Eapen ZJ; Filippatos GS; Gimpelewicz C; Greenberg B; Holbro T; Januzzi JL; Lanfear DE; Pang PS; Piña IL; Ponikowski P; Miller AB; Voors AA; Felker GM
    JACC Heart Fail; 2020 Dec; 8(12):999-1008. PubMed ID: 33189635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of serelaxin on mode of death in acute heart failure: results from the RELAX-AHF study.
    Felker GM; Teerlink JR; Butler J; Hernandez AF; Miller AB; Cotter G; Davison BA; Filippatos G; Greenberg BH; Ponikowski P; Voors AA; Hua TA; Severin TM; Unemori E; Metra M
    J Am Coll Cardiol; 2014 Oct; 64(15):1591-8. PubMed ID: 25301463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX-AHF-2 study.
    Teerlink JR; Voors AA; Ponikowski P; Pang PS; Greenberg BH; Filippatos G; Felker GM; Davison BA; Cotter G; Gimpelewicz C; Boer-Martins L; Wernsing M; Hua TA; Severin T; Metra M
    Eur J Heart Fail; 2017 Jun; 19(6):800-809. PubMed ID: 28452195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of serelaxin when added to standard of care in patients with acute heart failure: results from a PROBE study, RELAX-AHF-EU.
    Maggioni AP; López-Sendón J; Nielsen OW; Hallén J; Aalamian-Mattheis M; Wang Y; Ertl G
    Eur J Heart Fail; 2019 Mar; 21(3):322-333. PubMed ID: 30604559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating the Efficacy, Safety, and Tolerability of Serelaxin When Added to Standard Therapy in Asian Patients With Acute Heart Failure: Design and Rationale of RELAX-AHF-ASIA Trial.
    Sato N; Lam CS; Teerlink JR; Greenberg BH; Tsutsui H; Oh BH; Zhang J; Lefkowitz M; Hua TA; Holbro T; Marshood M; Wang XL; Ge J
    J Card Fail; 2017 Jan; 23(1):63-71. PubMed ID: 27825893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serelaxin in acute heart failure patients with preserved left ventricular ejection fraction: results from the RELAX-AHF trial.
    Filippatos G; Teerlink JR; Farmakis D; Cotter G; Davison BA; Felker GM; Greenberg BH; Hua T; Ponikowski P; Severin T; Unemori E; Voors AA; Metra M
    Eur Heart J; 2014 Apr; 35(16):1041-50. PubMed ID: 24316514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serelaxin in acute heart failure: Most recent update on clinical and preclinical evidence.
    Ghosh RK; Banerjee K; Tummala R; Ball S; Ravakhah K; Gupta A
    Cardiovasc Ther; 2017 Feb; 35(1):55-63. PubMed ID: 27727514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes.
    Metra M; Cotter G; Davison BA; Felker GM; Filippatos G; Greenberg BH; Ponikowski P; Unemori E; Voors AA; Adams KF; Dorobantu MI; Grinfeld L; Jondeau G; Marmor A; Masip J; Pang PS; Werdan K; Prescott MF; Edwards C; Teichman SL; Trapani A; Bush CA; Saini R; Schumacher C; Severin T; Teerlink JR;
    J Am Coll Cardiol; 2013 Jan; 61(2):196-206. PubMed ID: 23273292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial.
    Teerlink JR; Cotter G; Davison BA; Felker GM; Filippatos G; Greenberg BH; Ponikowski P; Unemori E; Voors AA; Adams KF; Dorobantu MI; Grinfeld LR; Jondeau G; Marmor A; Masip J; Pang PS; Werdan K; Teichman SL; Trapani A; Bush CA; Saini R; Schumacher C; Severin TM; Metra M;
    Lancet; 2013 Jan; 381(9860):29-39. PubMed ID: 23141816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Growth differentiation factor 15 (GDF-15) in patients admitted for acute heart failure: results from the RELAX-AHF study.
    Cotter G; Voors AA; Prescott MF; Felker GM; Filippatos G; Greenberg BH; Pang PS; Ponikowski P; Milo O; Hua TA; Qian M; Severin TM; Teerlink JR; Metra M; Davison BA
    Eur J Heart Fail; 2015 Nov; 17(11):1133-43. PubMed ID: 26333529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of serelaxin in subgroups of patients with acute heart failure: results from RELAX-AHF.
    Metra M; Ponikowski P; Cotter G; Davison BA; Felker GM; Filippatos G; Greenberg BH; Hua TA; Severin T; Unemori E; Voors AA; Teerlink JR
    Eur Heart J; 2013 Oct; 34(40):3128-36. PubMed ID: 23999454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutrophil-to-Lymphocyte Ratio and Outcomes in Patients Admitted for Acute Heart Failure (As Seen in the BLAST-AHF, Pre-RELAX-AHF, and RELAX-AHF Studies).
    Davison BA; Takagi K; Edwards C; Adams KF; Butler J; Collins SP; Dorobantu MI; Ezekowitz JA; Filippatos G; Greenberg BH; Levy PD; Masip J; Metra M; Pang PS; Ponikowski P; Severin TM; Teerlink JR; Teichman SL; Voors AA; Werdan K; Cotter G
    Am J Cardiol; 2022 Oct; 180():72-80. PubMed ID: 35933224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Representativeness of RELAX-AHF clinical trial population in acute heart failure.
    Wang TS; Hellkamp AS; Patel CB; Ezekowitz JA; Fonarow GC; Hernandez AF
    Circ Cardiovasc Qual Outcomes; 2014 Mar; 7(2):259-68. PubMed ID: 24594552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of serelaxin in acute heart failure patients with renal impairment: results from RELAX-AHF.
    Liu LC; Voors AA; Teerlink JR; Cotter G; Davison BA; Felker GM; Filippatos G; Chen Y; Greenberg BH; Ponikowski P; Pang PS; Prescott MF; Hua TA; Severin TM; Metra M
    Clin Res Cardiol; 2016 Sep; 105(9):727-37. PubMed ID: 27017514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Serelaxin in Patients with Acute Heart Failure.
    Metra M; Teerlink JR; Cotter G; Davison BA; Felker GM; Filippatos G; Greenberg BH; Pang PS; Ponikowski P; Voors AA; Adams KF; Anker SD; Arias-Mendoza A; Avendaño P; Bacal F; Böhm M; Bortman G; Cleland JGF; Cohen-Solal A; Crespo-Leiro MG; Dorobantu M; Echeverría LE; Ferrari R; Goland S; Goncalvesová E; Goudev A; Køber L; Lema-Osores J; Levy PD; McDonald K; Manga P; Merkely B; Mueller C; Pieske B; Silva-Cardoso J; Špinar J; Squire I; Stępińska J; Van Mieghem W; von Lewinski D; Wikström G; Yilmaz MB; Hagner N; Holbro T; Hua TA; Sabarwal SV; Severin T; Szecsödy P; Gimpelewicz C;
    N Engl J Med; 2019 Aug; 381(8):716-726. PubMed ID: 31433919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serelaxin : a potential new drug for the treatment of acute heart failure.
    Neverova N; Teerlink JR
    Expert Opin Investig Drugs; 2014 Jul; 23(7):1017-26. PubMed ID: 24865798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinct Comorbidity Clusters in Patients With Acute Heart Failure: Data From RELAX-AHF-2.
    Gomez KA; Tromp J; Figarska SM; Beldhuis IE; Cotter G; Davison BA; Felker GM; Gimpelewicz C; Greenberg BH; Lam CSP; Voors AA; Metra M; Teerlink JR; van der Meer P
    JACC Heart Fail; 2024 Oct; 12(10):1762-1774. PubMed ID: 38970586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Day vs night: Does time of presentation matter in acute heart failure? A secondary analysis from the RELAX-AHF trial.
    Pang PS; Teerlink JR; Boer-Martins L; Gimpelewicz C; Davison BA; Wang Y; Voors AA; Severin T; Ponikowski P; Hua TA; Greenberg BH; Filippatos G; Felker GM; Cotter G; Metra M
    Am Heart J; 2017 May; 187():62-69. PubMed ID: 28454809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of age on clinical outcomes and response to serelaxin in patients with acute heart failure: An analysis from the RELAX-AHF-2 trial.
    Inciardi RM; Staal L; Davison B; Lombardi CM; Postmus D; Felker MG; Filippatos G; Greenberg B; Pang PS; Ponikowski P; Severin T; Gimpelewicz C; Teerlink J; Cotter G; Voors AA; Metra M
    Eur J Heart Fail; 2024 Sep; ():. PubMed ID: 39240040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serelaxin in acute heart failure patients with and without atrial fibrillation: a secondary analysis of the RELAX-AHF trial.
    Filippatos G; Farmakis D; Metra M; Cotter G; Davison BA; Felker GM; Greenberg BH; Hua TA; Pang PS; Ponikowski P; Qian M; Severin TA; Voors AA; Teerlink JR
    Clin Res Cardiol; 2017 Jun; 106(6):444-456. PubMed ID: 28150186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.